Abstract
Introduction
Non-functioning pituitary adenomas (NFPAs) are in general large tumors that present with symptoms secondary to local pressure on adjacent structures. Transsphenoidal surgery is the first line of treatment but residual tumor mass is often detected post-operatively. Medical therapy, in any stage of tumor management, is not well established.
Methods
A literature search was performed to review the available data on medical treatment of NFPAs.
Results
Medications investigated for the treatment of NFPAs include dopamine receptor agonists (DA) and somatostatin receptor ligands. Randomized controlled trials are lacking, but available data suggest that DA have a positive effect on tumor remnant stabilization after surgery and could be considered in this setting. Temozolomide is reserved for aggressive tumors, although future studies are required.
Conclusions
NFPA are often not amenable to complete surgical resection. Conservative follow-up after surgery is associated with a high prevalence of tumor remnant progression. DA therapy may prevent residual tumor enlargement in over 85% of these patients, with a substantial consequent reduction in the need for repeat surgery or radiation therapy. It is our view that DA treatment should be routinely considered for the management of NFPA patients with incompletely resected tumors.
Similar content being viewed by others
References
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613–619. https://doi.org/10.1002/cncr.20412
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769–4775. https://doi.org/10.1210/jc.2006-1668
Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72(3):377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x
Fontana E, Gaillard R (2009) Epidemiology of pituitary adenoma: results of the first Swiss study. Rev Med Suisse 5(223):2172–2174
Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab 95(9):4268–4275. https://doi.org/10.1210/jc.2010-0537
Molitch ME (2014) Nonfunctioning pituitary tumors. Handb Clin Neurol 124:167–184. https://doi.org/10.1016/B978-0-444-59602-4.00012-5
Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, Wu ZB (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4):333–342. https://doi.org/10.1159/000339823
Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best practice & research. Clin Endocrinol Metab 23(5):625–638. https://doi.org/10.1016/j.beem.2009.05.005
Iglesias P, Arcano K, Trivino V, Garcia-Sancho P, Diez JJ, Villabona C, Cordido F (2017) Prevalence, clinical features, and natural history of incidental clinically non-functioning pituitary adenomas. Horm Metab Res. https://doi.org/10.1055/s-0043-115645
Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 156(2):203–216. https://doi.org/10.1530/eje.1.02326
Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. https://doi.org/10.1007/s00401-017-1769-8
Sanchez-Tejada L, Sanchez-Ortiga R, Lamas C, Camara R, Riesgo P, Fajardo C, Aranda FI, Pico A (2017) Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. PLoS ONE 12(7):e0180039. https://doi.org/10.1371/journal.pone.0180039
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol. https://doi.org/10.1007/s12022-017-9498-z
Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 132(8):1231–1240. https://doi.org/10.1043/1543-2165(2008)132[1231:PPPWDT]2.0.CO;2
Larysz D, Blamek S, Rudnik A (2012) Clinical aspects of molecular biology of pituitary adenomas. Folia Neuropathol 50(2):110–117
Greenman Y, Stern N (2015) Optimal management of non-functioning pituitary adenomas. Endocrine 50(1):51–55. https://doi.org/10.1007/s12020-015-0685-8
Dekkers OM, Pereira AM, Roelfsema F, Voormolen JH, Neelis KJ, Schroijen MA, Smit JW, Romijn JA (2006) Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91(5):1796–1801. https://doi.org/10.1210/jc.2005-2552
Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108(3):525–532. https://doi.org/10.3171/JNS/2008/108/3/0525
Woollons AC, Hunn MK, Rajapakse YR, Toomath R, Hamilton DA, Conaglen JV, Balakrishnan V (2000) Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol 53(6):713–717
Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, French Endocrinology Society Non-functioning Pituitary Adenoma Work Group (2015) Management of clinically non-functioning pituitary adenoma. Ann Endocrinol 76(3): 239–247. https://doi.org/10.1016/j.ando.2015.04.002
Kuo JS, Barkhoudarian G, Farrell CJ, Bodach ME, Tumialan LM, Oyesiku NM, Litvack Z, Zada G, Patil CG, Aghi MK (2016) Congress of neurological surgeons systematic review and evidence-based guideline on surgical techniques and technologies for the management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79(4):E536–E538. https://doi.org/10.1227/NEU.0000000000001390
Lucas JW, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G (2016) Congress of neurological surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79(4):E533–E535. https://doi.org/10.1227/NEU.0000000000001389
Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine S (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(4):894–904. https://doi.org/10.1210/jc.2010-1048
Asemota AO, Ishii M, Brem H, Gallia GL (2017) Comparison of complications, trends, and costs in endoscopic vs microscopic pituitary surgery: analysis from a US health claims database. Neurosurgery 81(3):458–472. https://doi.org/10.1093/neuros/nyx350
Iglesias P, Arcano K, Trivino V, Garcia-Sancho P, Diez JJ, Cordido F, Villabona C (2017) Non-functioning pituitary adenoma underwent surgery: a multicenter retrospective study over the last four decades (1977–2015). Eur J Intern Med 41:62–67. https://doi.org/10.1016/j.ejim.2017.03.023
Chittiboina P (2017) iMRI during transsphenoidal surgery. Neurosurg Clin N Am 28(4):499–512. https://doi.org/10.1016/j.nec.2017.05.005
Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW, Romijn JA, Pereira AM (2007) The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 156(2):217–224. https://doi.org/10.1530/eje.1.02334
Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108(4):736–745. https://doi.org/10.3171/JNS/2008/108/4/0736
Minniti G, Clarke E, Scaringi C, Enrici RM (2016) Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother 21(4):370–378. https://doi.org/10.1016/j.rpor.2014.09.004
Yamanaka R, Abe E, Sato T, Hayano A, Takashima Y (2017) Secondary intracranial tumors following radiotherapy for pituitary adenomas: a systematic review. Cancers. https://doi.org/10.3390/cancers9080103
Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163(2):193–200. https://doi.org/10.1530/EJE-10-0255
O’Sullivan EP, Woods C, Glynn N, Behan LA, Crowley R, O’Kelly P, Smith D, Thompson CJ, Agha A (2009) The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin Endocrinol 71(5):709–714. https://doi.org/10.1111/j.1365-2265.2009.03583.x
Gatto F, Hofland LJ (2011) The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 18(6):R233–R251. https://doi.org/10.1530/ERC-10-0334
Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP, Kineman RD, Gadelha MR (2009) Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94(6):1931–1937. https://doi.org/10.1210/jc.2008-1826
Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L (2001) Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14(3):329–336
Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A, Stalla GK (1998) Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 83(4):1368–1375. https://doi.org/10.1210/jcem.83.4.4685
Verde G, Oppizzi G, Chiodini PG, Dallabonzana D, Luccarelli G, Liuzzi A (1985) Effect of chronic bromocriptine administration on tumor size in patients with “nonsecreting” pituitary adenomas. J Endocrinol Investig 8(2):113–115. https://doi.org/10.1007/BF03350660
van Schaardenburg D, Roelfsema F, van Seters AP, Vielvoye GJ (1989) Bromocriptine therapy for non-functioning pituitary adenoma. Clin Endocrinol 30(5):475–484
Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89(4):1674–1683. https://doi.org/10.1210/jc.2003-030859
Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R, Paschke R (2001) Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4(3):173–178
Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175(1):63–72. https://doi.org/10.1530/EJE-16-0206
de Herder WW, Reijs AE, Feelders RA, van Aken MO, Krenning EP, Tanghe HL, van der Lely AJ, Kwekkeboom DJ (2006) Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur J Endocrinol 155(5):717–723. https://doi.org/10.1530/eje.1.02281
Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF (2013) Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16(2):189–194. https://doi.org/10.1007/s11102-012-0403-y
Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, Gadelha MR (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin Endocrinol 82(5):739–746. https://doi.org/10.1111/cen.12684
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356(1):39–46. https://doi.org/10.1056/NEJMoa054830
Auriemma RS, Grasso LF, Pivonello R, Colao A (2016) The safety of treatments for prolactinomas. Exp Opin Drug Saf 15(4):503–512. https://doi.org/10.1517/14740338.2016.1151493
Caputo C, Prior D, Inder WJ (2015) The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. The Lancet 3(11):906–913. https://doi.org/10.1016/S2213-8587(14)70212-8
Eigler T, Ben-Shlomo A (2014) Somatostatin system: molecular mechanisms regulating anterior pituitary hormones. J Mol Endocrinol 53(1):R1–R19. https://doi.org/10.1530/JME-14-0034
Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G (2009) Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 10(2):111–123. https://doi.org/10.1007/s11154-008-9107-z
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700
Nazato DM, Abucham J (2017) Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center. J Endocrinol Investig. https://doi.org/10.1007/s40618-017-0770-3
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A (2015) Treatment of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831. https://doi.org/10.1210/jc.2015-1818
Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, Pellegata NS (2015) SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer 22(1):111–119. https://doi.org/10.1530/ERC-14-0472
Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15(4):905–915. https://doi.org/10.1677/ERC-08-0181
Fusco A, Giampietro A, Bianchi A, Cimino V, Lugli F, Piacentini S, Lorusso M, Tofani A, Perotti G, Lauriola L, Anile C, Maira G, Pontecorvi A, De Marinis L (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4):571–578. https://doi.org/10.1007/s11102-011-0370-8
Zawada NB, Kunert-Radek J, Pawlikowski M, Pisarek H, Radek M (2016) An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. Endokrynol Polska 67(3):292–298. https://doi.org/10.5603/EP.a2016.0043
Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC (2004) Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 89(10):5181–5188. https://doi.org/10.1210/jc.2003-031954
Ibanez-Costa A, Rivero-Cortes E, Vazquez-Borrego MC, Gahete MD, Jimenez-Reina L, Venegas-Moreno E, de la Riva A, Arraez MA, Gonzalez-Molero I, Schmid HA, Maraver-Selfa S, Gavilan-Villarejo I, Garcia-Arnes JA, Japon MA, Soto-Moreno A, Galvez MA, Luque RM, Castano JP (2016) Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol 231(2):135–145. https://doi.org/10.1530/JOE-16-0332
Ciato D, Mumbach AG, Paez-Pereda M, Stalla GK (2017) Currently used and investigational drugs for cushings disease. Exp Opin Investig Drugs 26(1):75–84. https://doi.org/10.1080/13543784.2017.1266338
Priola SM, Esposito F, Cannavo S, Conti A, Abbritti RV, Barresi V, Baldari S, Ferrau F, Germano A, Tomasello F, Angileri FF (2017) Aggressive pituitary adenomas: the dark side of the moon. World Neurosurg 97:140–155. https://doi.org/10.1016/j.wneu.2016.09.092
De Caro MDB, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G, Cappabianca P (2017) A typical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40(1):105–114. https://doi.org/10.1007/s10143-016-0740-9
Halevy C, Whitelaw BC (2017) How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary 20(2):261–266. https://doi.org/10.1007/s11102-016-0745-y
Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol metab 98(3):1130–1136. https://doi.org/10.1210/jc.2012-2924
Campdera M, Palacios N, Aller J, Magallon R, Martin P, Saucedo G, Lilienfeld H, Estrada J (2016) Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. Pituitary 19(2):158–166. https://doi.org/10.1007/s11102-015-0694-x
Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol 76(6):769–775. https://doi.org/10.1111/j.1365-2265.2012.04381.x
Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592–4599. https://doi.org/10.1210/jc.2010-0644
McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Investig 41(10):1133–1148. https://doi.org/10.1111/j.1365-2362.2011.02520.x
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1–G24. https://doi.org/10.1530/EJE-17-0796
Fani M, Nicolas GP, Wild D (2017) Somatostatin receptor antagonists for imaging and therapy. J Nucl Med 58(Suppl 2):61S–66S. https://doi.org/10.2967/jnumed.116.186783
Komor J, Reubi JC, Christ ER (2014) Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary 17(3):227–231. https://doi.org/10.1007/s11102-013-0494-0
Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F, Cannavo S (2012) First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 15(Suppl 1):S57–S60. https://doi.org/10.1007/s11102-011-0373-5
Maclean J, Aldridge M, Bomanji J, Short S, Fersht N (2014) Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary 17(6):530–538. https://doi.org/10.1007/s11102-013-0540-y
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Even-Zohar, N., Greenman, Y. Management of NFAs: medical treatment. Pituitary 21, 168–175 (2018). https://doi.org/10.1007/s11102-018-0865-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-018-0865-7